ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Advocating for Yourself or Loved Ones When Bladder Cancer is Suspected

photo

SPONSORED CONTENT -- (StatePoint) If you or someone you know may have bladder cancer, being well informed could get you the best diagnosis and treatment. In fact, according to an article published in “Urologic Oncology,” in 46.5% of the cases where a bladder was removed because of advanced cancer, a very serious type of tumor called carcinoma in situ (CIS) had been missed in past transurethral resection of bladder tumor (TURBT) procedures. This alarming statistic magnifies the need for urologists to have enhanced tumor visibility during TURBTs. There is one procedure that can offer visibility of hard-to-see tumors including CIS; it’s called Blue Light Cystoscopy (BLC). Here’s what to know:

TURBT can be a critical diagnostic step when done properly and precisely. The TURBT provides essential information regarding the number of tumors, tumor sizes, locations and depth of invasion. All these factors significantly inform the identification of a patient’s risk category, which can subsequently impact treatment decisions.

Currently, White Light Cystoscopy is most commonly used for a patient’s first TURBT and is considered the standard level of care. However, research suggests that using White Light Cystoscopy alone may be inadequate, causing:

• Incomplete tumor resection: After one year, there is a rate of up to 61% of non-muscle invasive bladder cancer recurrence, suggesting incomplete tumor resection when using only White Light Cystoscopy.

• New tumor growth: Up to 70% of patients have tumors recur after standard TURBT.

• Tumors found during subsequent TURBT procedures: Up to 86% of residual tumors are found at the original resection site after initial white-light TURBT.

So, how can patients ensure better diagnostics and treatment? Experts say that asking for BLC during the first TURBT is a great way to advocate for yourself or a loved one. BLC is a technology that allows urologists to see tumors that white light alone may miss. Unfortunately, it is not always utilized at the first encounter with the patient.

Suzanne B. Merrill, MD, FACS, Colorado Urology said, “By using Blue Light Cystoscopy for first TURBT, urologists can more completely assess the bladder, achieve greater tumor eradication and provide more data for appropriate diagnosis. Doing the procedure with enhanced visibility right at the start of patient care can better establish the appropriate treatment regimen for each patient and lower the risk of disease recurrence.”

Dr. Merrill recommends that patients and their loved ones be their own advocates when it comes to their diagnosis.

Need some tips for how to talk to your urologist about TURBT and BLC? Follow these steps:

1. Find a trusted urologist in your area.

2. Inquire about BLC with your urologist.

3. Explain to your urologist that you’re interested in BLC at your first TURBT to ensure better tumor visibility.

4. If your urologist does not offer BLC, find one that does.

To find locations that offer BLC, visit https://rebrand.ly/BLC-Locations.

“When it comes to your medical care, you should always feel comfortable advocating for yourself,” says Dr. Merrill. “You may need to speak to more than one urologist, but doing so can mean better outcomes for your health in the long term.”

This article is sponsored by Photocure, Inc.

*****

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.